Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new ...

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check ...

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly said it received Food and Drug Administration approval ...

Eli Lilly has agreed to acquire Scorpion Therapeutics' breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly and Company LLY dropped 6.6% in the ... prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. Of these, Eli Lilly takes the ...